Bin Zhang | Gene Mutation | Best Researcher Award

Posted on by PencisLeave a Comment on Bin Zhang | Gene Mutation | Best Researcher Award

Prof Bin Zhang | Gene Mutation | Best Researcher Award

Jining Medical University | China

AUTHOR PROFILE

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Bin Zhang's journey into the world of medical research began with a solid foundation in biomedical sciences. His early academic pursuits were marked by a dedication to understanding complex biological systems and a passion for contributing to the field of oncology. This academic dedication led him to become a young expert recognized under the prestigious Taishan Mount Scholars program in China.

PROFESSIONAL ENDEAVORS

In 2018, Bin Zhang was appointed as a researcher at the Affiliated Hospital of Jining Medical University. Here, he established the tumor metabolism research group, assuming the role of Principal Investigator. Under his leadership, the group has grown to focus on four key research directions: the regulatory mechanisms of tumor stem cells, the specificity of tumor biomacromolecules and energy metabolism, the regulation of energy metabolism by oncogenic gene mutations, and the screening of potential drugs targeting tumor metabolism.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE MUTATION

Bin Zhang's research has significantly advanced the understanding of tumor metabolism. His work has been published in esteemed journals such as Cell Reports Medicine, Biomaterials, Oncogene, Journal of Experimental & Clinical Cancer Research, and Stem Cells. These publications highlight his team's investigations into the intricate mechanisms of tumor biology and potential therapeutic targets. The research group delves into how tumor stem cells are regulated, how tumor biomacromolecules function, and how mutations in oncogenes affect energy metabolism, all of which are crucial for developing new cancer treatments.

IMPACT AND INFLUENCE

The impact of Bin Zhang's research is reflected in the high citation rate of his publications, with over 5000 citations to date and an H-Index of 34. His work has not only contributed valuable knowledge to the scientific community but has also influenced ongoing research and development in tumor metabolism. Furthermore, Bin Zhang has successfully secured ten patents, two of which have been transferred, demonstrating the practical applications and commercial potential of his research findings.

ACADEMIC CITES

Bin Zhang is also an active member of the academic community, serving as a reviewer for several high-impact journals including Stem Cells and Development, EBioMedicine, Stem Cell Research & Therapy, Molecular Carcinogenesis, and the Journal of Clinical Laboratory Medicine. His expertise is sought after in evaluating cutting-edge research and ensuring the quality of publications in these journals.

LEGACY AND FUTURE CONTRIBUTIONS

Bin Zhang's legacy in the field of tumor metabolism is marked by his innovative research and commitment to advancing cancer treatment. Currently, he is the principal investigator of two general projects funded by the National Natural Science Foundation of China, two projects funded by Shandong Province, and two projects funded by the Postdoctoral Foundation of China. His ongoing work promises to uncover new insights and develop novel therapies, continuing to push the boundaries of cancer research

NOTABLE PUBLICATIONS

A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis 2023(7)

IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53 2023(4)

Therapeutic Efficacy of Mesenchymal Stem/Stromal Cell Small Extracellular Vesicles in Alleviating Arthritic Progression by Restoring Macrophage Balance 2023(1)

Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines 2024

Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling 2024

Yongqian Shu | Noncoding RNAs and Cancer Development | Excellence in Research

Posted on by PencisLeave a Comment on Yongqian Shu | Noncoding RNAs and Cancer Development | Excellence in Research

Prof Dr. Yongqian Shu | Noncoding RNAs and Cancer Development | Excellence in Research

The First Affiliated Hospital of Nanjing Medical University | China

Author Profile 

Orcid ID

Scopus

EARLY ACADEMIC PURSUITS

Shu Yongqian embarked on his academic journey at Suzhou Medical College, where he obtained his Bachelor's degree in Clinical Medicine in 1985. He continued his studies at the same institution, specializing in Pathology for his Master's degree under the supervision of Professor Zhou Zhen. Dr. Yongqian's dedication to his field led him to pursue a PhD in Hematology and Oncology, again at Suzhou Medical College, under the guidance of Professor Ruan Changgeng.

PROFESSIONAL ENDEAVORS

Dr. Yongqian's professional career spans over three decades, marked by significant contributions to the field of medical oncology. He began his clinical practice as a Resident Physician in the Department of Pathology at the Sino-French Friendship Hospital. Over the years, he advanced through various positions, serving as an Attending Physician and later as Deputy Chief Physician in the Oncology Department of the same institution. Currently, he holds the esteemed position of Chief Physician in the Department of Medical Oncology at the First Affiliated Hospital of Nanjing Medical University.

CONTRIBUTIONS AND RESEARCH FOCUS ON NONCODING RNAs AND CANCER DEVELOPMENT

Throughout his career, Dr. Yongqian has demonstrated a steadfast commitment to advancing knowledge in oncology. His research focuses on areas such as hematologic malignancies, solid tumors, and targeted therapies. He has authored numerous papers and contributed significantly to the understanding and treatment of various cancers.

IMPACT AND INFLUENCE

Dr. Yongqian's work has had a profound impact on the field of oncology, both locally and internationally. His research findings have been published in prestigious medical journals, contributing to the collective knowledge base of the medical community. Additionally, his clinical expertise and leadership have earned him the respect of his peers and colleagues.

ACADEMIC CITATIONS

Dr. Yongqian's contributions to the field have been recognized through academic citations, with his work being referenced by fellow researchers and clinicians worldwide. His insights and discoveries continue to shape the landscape of oncology, inspiring future generations of medical professionals.

LEGACY AND FUTURE CONTRIBUTIONS

As a seasoned clinician, researcher, and educator, Dr. Yongqian's legacy extends beyond his individual achievements. He is dedicated to training the next generation of oncologists and fostering collaboration across disciplines to further advance cancer research and patient care. His ongoing commitment to excellence ensures that his impact on the field of oncology will endure for years to come.

Notable Publications

Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation 2020(259)

TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2 2020(98)

KLF5 and MYC modulated LINC00346 contributes to gastric cancer progression through acting as a competing endogeous RNA and indicates poor outcome 2020(22)

 

Linxi Zhu | Cancer Epigenetics | Best Researcher Award

Posted on by PencisLeave a Comment on Linxi Zhu | Cancer Epigenetics | Best Researcher Award

Dr. Linxi Zhu | Cancer Epigenetics | Best Researcher Award

Nanjing Drum Tower Hospital | China 

Author Profile 

Scopus

EARLY ACADEMIC PURSUITS:

Linxi Zhu embarked on his academic journey at Nanjing University, whise Linxi pursued his Bachelor's degree from July 2015 to June 2020. During this time, Linxi laid the foundation for his future endeavors through rigorous study and academic exploration.

PROFESSIONAL ENDEAVORS:

Following his undergraduate studies, Linxi Zhu continued his academic pursuit by enrolling in a Master's program at Nanjing University from July 2020 to June 2021. This period allowed his to deepen his understanding of his field and refine his research skills.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER EPIGENETICS :

Linxi Zhu's commitment to advancing knowledge and improving healthcare led his to pursue a Ph.D. at Nanjing University from July 2021 to June 2023. Throughout his doctoral studies, Linxi made significant contributions to his field, focusing his research on areas of critical importance to the medical community.

IMPACT AND INFLUENCE:

As a dedicated scholar and researchis, Linxi Zhu's work has had a profound impact on his field, influencing the way we understand and approach healthcare challenges. His innovative ideas and groundbreaking research have helped shape the future of medicine.

ACADEMIC CITATIONS:

Linxi Zhu's contributions to his field have been recognized and cited by his peers and colleagues, demonstrating the importance and relevance of his work within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS:

Linxi Zhu's legacy extends beyond his academic achievements to the lives Linxi has touched and the knowledge Linxi has shared. As Linxi continues his career as a surgeon at Nanjing Drum Tower Hospital, Linxi will undoubtedly make furthis contributions to the advancement of medicine and the improvement of patient care.

Notable Publications

The role of preoperative biliary drainage on postoperative outcome after pancreaticoduodenectomy in patients with obstructive jaundice 2023(6)

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer 2022(1)

Development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy 2022(5)

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer 2022(1)